دورية أكاديمية
Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study
| العنوان: | Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study |
|---|---|
| المؤلفون: | Briassoulis, E. Ch, Pentheroudakis, George, Timotheadou, H., Rammou, D., Pavlidis, Nicholas, Fountzilas, George |
| المساهمون: | Pavlidis, Nicholas 0000-0002-2195-9961, Pentheroudakis, George 0000-0002-6632-2462 |
| المصدر: | Anti-Cancer Drugs |
| سنة النشر: | 2004 |
| المجموعة: | University of Cyprus: Gnosis Institutional Repository / Ιδρυματικό αποθετήριο Πανεπιστημίου Κύπρου "Γνῶσις" |
| مصطلحات موضوعية: | Greece, Article, Human, Humans, Adult, Aged, Female, Middle aged, Advanced cancer, Cancer combination chemotherapy, Chemotherapy, Priority journal, Alopecia, Anemia, Anorexia, Antineoplastic combined chemotherapy protocols, Arthralgia, Bone marrow suppression, Clinical article, Clinical trial, Constipation, Diarrhea, Docetaxel, Drug infusion, Fatigue, Febrile neutropenia, Infection, Leukopenia, Mucosa inflammation, Myalgia |
| الوصف: | We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine the toxicity spectrum, and define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended optimal dose (ROD) of irinotecan infused over 24 h and followed by a 1-h infusion of 30 mg/m2 docetaxel. Starting dose for irinotecan was 30 mg/m2 and escalation proceeded at 30 mg/m2 increments, in cohorts of three to six patients until the MTD was reached. A dose between the MTD and the previous level was explored to further define the ROD. Thirty-two patients with advanced refractory cancers (median age 64, 19 male) received 190 treatment courses at five dosing levels of irinotecan: 30 mg/m2 (n=6 patients), 60 (n=3), 90 (n=7), 120 (n=8) and 105 (n=8). The MTD and ROD was 120/30 and 105/30 mg/m2. DLTs were diarrhea and neutropenia. Antitumor activity was modest The ROD of biweekly administration of 24-h irinotecan followed by 1-h docetaxel is 105 and 30 mg/m2, respectively. The low hematological toxicity and modest activity observed leave questions concerning the optimal timing of this combination. © 2004 Lippincott Williams & Wilkins. ; 15 ; 8 ; 747 ; 752 |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://gnosis.library.ucy.ac.cy/handle/7/41476Test |
| DOI: | 10.1097/00001813-200409000-00002 |
| الإتاحة: | https://doi.org/10.1097/00001813-200409000-00002Test https://gnosis.library.ucy.ac.cy/handle/7/41476Test |
| رقم الانضمام: | edsbas.BA620CEF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/00001813-200409000-00002 |
|---|